215
Views
3
CrossRef citations to date
0
Altmetric
Research Articles

Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs

ORCID Icon, ORCID Icon, ORCID Icon, &
Pages 7726-7743 | Received 03 Aug 2020, Accepted 05 Mar 2021, Published online: 22 Mar 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Shabbir Muhammad, Afsheen Saba, Rasheed Ahmad Khera, Abdullah. G. Al-Sehemi, H. Algarni, Javed Iqbal, Mohammad Y. Alshahrani & Aijaz Rasool Chaudhry. (2022) Virtual screening of potential inhibitor against breast cancer-causing estrogen receptor alpha (ERα): molecular docking and dynamic simulations. Molecular Simulation 48:13, pages 1163-1174.
Read now

Articles from other publishers (2)

Asmaa M. Taha, Wafaa S. Hassan, Manal S. Elmasry & Rania A. Sayed. (2023) A validated eco-friendly HPLC-FLD for analysis of the first approved antiviral remdesivir with other potential add-on therapies for COVID-19 in human plasma and pharmaceuticals. Analytical Methods.
Crossref
Habibu Tijjani, Adegbenro P. Adegunloye, Auwalu Uba, Joseph O. Adebayo, Gideon A. Gyebi & Ibrahim M. Ibrahim. (2022) Pharmacoinformatic study of inhibitory potentials of selected flavonoids against papain-like protease and 3-chymotrypsin-like protease of SARS-CoV-2. Clinical Phytoscience 8:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.